| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
BOSTON—PerkinElmer Inc.'s, acquisition of Avalon Instruments Limited, based in Belfast, Northern Ireland, will broaden PerkinElmer's molecular spectroscopy product portfolio with a Raman spectrom­eter line.
 
Simon Wells, molecular spectroscopy business manager, life and analytical scienc­es, at PerkinElmer says Avalon's dispersive Raman products complement PerkinElmer's existing ultraviolet and infrared spectrome­try offerings. "From a technical point of view, this is a very strong fit with PerkinElmer's current technology and product portfolio." Under the acquisition, which was finalized on September 1, PerkinElmer acquired all Avalon's intellectual property and products, including Raman-based microscopes and spectrometers. Financial terms of the deal were not released.
 
For Andrew Dennis, who founded Avalon six years ago and now serves as Raman spec­troscopy business leader at PerkinElmer, the acquisition brings opportunities to pro­vide better sales channels, installation, and support for Avalon's instruments. "Having a very good technology or very good products is only one part of the jigsaw puzzle," he says. "The fit between us and PerkinElmer is really, really great."
 
Manufacturing the Raman line at PerkinElmer's Llantrisant, South Wales, facility will reduce lead times for delivery and take advan­tage of existing capabilities for assembling equipment with rela­tively unusual echelle technology, which is in both PerkinElmer's atomic spectrometers and Avalon's Raman spectrometers. Moving manufacture to Wales also stream­lines Belfast operations by freeing up Dennis's R&D team to work on product improvements and new applications rather than assembly and customer service.
 
Another plus under the acqui­sition is that PerkinElmer has increased instrument docu­mentation on the Raman line. "Within the drug discovery area the appropriate documentation which proves the integrity of the results is very, very important," says Dennis, who believes that PerkinElmer's efforts to pursue more rigorous compliance should make the equipment even more appealing to researchers.
 
Dennis and Wells say that with high resolution and spectral inten­sity, Avalon's Raman spectrom­eters are particularly useful to drug discovery researchers study­ing polymorphisms. "The perfor­mance that we get from these new instruments really fills a void in the way Raman is presented to industries like the pharmaceutical industry," says Wells.
 
PerkinElmer plans to roll out a full advertising campaign and global launch for the Raman line this fall; most of Avalon's prod­ucts will remain, at least for the short term. "We wouldn't be excited about having this new product line without being com­mitted to its future," says Wells. Although he says Raman technol­ogy has had a reputation for being expensive and time-consuming, PerkinElmer hopes to reach more customers by demonstrating that Avalon's products, which will be sold under the PerkinElmer label, require less time and money for operation and maintenance than people might think.
 
Performance and ease of use are particularly important for prod­ucts like Avalon's high-throughput push-button spectrometer, believes Dennis. The company "put a lot of effort into giving the user high quality of results but making the instrument in such a way that they don't have to adjust the instru­ment, they don't have to calibrate the instrument, they don't really have to support the product. The scientists can concentrate on their science and the instrument takes care of itself."

About the Author

Related Topics

Published In

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue